Theraclion’s Sonovein® Receives Essential Certification
In a significant step forward, Theraclion, a French MedTech innovator, announced that its Sonovein® platform has successfully met the China‘s GB 9706.1-2020 medical electrical equipment safety standard. This certification aligns with the internationally recognized IEC 60601-1 framework and confirms that Sonovein® adheres to the latest safety requirements for medical devices in China. The approval validates the platform’s design and manufacturing integrity while confirming its compliance with the stringent technical and safety standards set by the National Medical Products Administration (NMPA) of China.
This achievement is a crucial milestone for Theraclion, as it represents one of the necessary steps toward securing market authorization in a country recognized as one of the largest and most rapidly evolving markets for advanced medical technologies. The certification not only highlights the robustness of Sonovein® but also demonstrates its capability to operate safely and effectively within the regulatory framework established by the NMPA.
Pathway to Market Authorization
With the successful certification of Sonovein®, Theraclion is now poised to advance its international expansion strategy significantly. This development is expected to enhance the company’s efforts to deliver its innovative non-invasive ultrasound technology to a wider patient demographic. The Sonovein® system utilizes High-Intensity Focused Ultrasound (HIFU) techniques that do not require surgical incisions or operating rooms, positioning it as a viable alternative for treating varicose veins.
According to company representatives, this certification marks a pivotal moment that sets the stage for future commercialization in China. The approval ensures that Sonovein® fulfills a core prerequisite in the NMPA’s approval process, moving Theraclion closer to making its advanced treatment options available in one of the most promising markets for healthcare technology.
About Theraclion
Founded with a commitment to revolutionize medical treatment through non-invasive techniques, Theraclion specializes in the development of HIFU technology. The company’s Sonovein® system, which has already been implemented in various healthcare centers around the globe, is designed to potentially replace millions of traditional surgical procedures annually. Although Sonovein® is not yet available for sale in the U.S., it has been utilized in over 3,500 procedures worldwide.
For further details about Theraclion and its innovative technologies, interested parties are encouraged to visit the official website or connect via their LinkedIn profile. The company is also listed on Euronext Growth Paris, reinforcing its commitment to advancing healthcare through cutting-edge technology.
Related
